Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280499295> ?p ?o ?g. }
- W4280499295 endingPage "1371" @default.
- W4280499295 startingPage "1357" @default.
- W4280499295 abstract "Vascular endothelial growth factor (VEGF) is a critical regulator of malignant pleural effusion (MPE) in non-small-cell lung cancer (NSCLC). Bevacizumab (BEV) and apatinib (APA) are novel VEGF blockers that inhibit lung cancer cell proliferation and the development of pleural effusion.In this study, we established Lewis lung cancer (LLC) xenograft mouse models to compare the therapeutic effect of APA and BEV in combination with cisplatin (CDDP) against MPE. The anti-tumour and anti-angiogenic effects of this combination therapy were evaluated by 18F-FDG PET/CT imaging, TUNEL assay and Immunohistochemistry.The triple drug combination significantly prolonged the overall survival of the tumour-bearing mice by reducing MPE and glucose metabolism and was more effective in lowering VEGF/soluble VEGFR-2 levels in the serum and pleural exudates compared to either of the monotherapies. Furthermore, CDDP + APA + BEV promoted in vivo apoptosis and decreased microvessel density.Mechanistically, LLC-induced MPE was inhibited by targeting the VEGF-MEK/ERK pathways. Further studies are needed to establish the synergistic therapeutic effect of these drugs in NSCLC patients with MPE.KEY MESSAGESCombined treatment of MPE with apatinib, bevacizumab and cisplatin can prolong the survival time of mice, reduce the content of MPE, decrease the SUVmax of thoracic tumour tissue, down-regulate the content of VEGF and sVEGFR-2 in serum and pleural fluid, and promote the apoptosis of tumour cells. Angiogenesis and MPE formation can be inhibited by down-regulation of HIF-1α, VEGF, VEGFR-2, MEK1 and MMP-2 molecular signalling pathway proteins." @default.
- W4280499295 created "2022-05-22" @default.
- W4280499295 creator A5008873401 @default.
- W4280499295 creator A5012949859 @default.
- W4280499295 creator A5032043555 @default.
- W4280499295 creator A5036184868 @default.
- W4280499295 creator A5056080574 @default.
- W4280499295 creator A5063187243 @default.
- W4280499295 creator A5063794764 @default.
- W4280499295 creator A5064813580 @default.
- W4280499295 creator A5064848746 @default.
- W4280499295 creator A5074051259 @default.
- W4280499295 creator A5090192901 @default.
- W4280499295 date "2022-05-11" @default.
- W4280499295 modified "2023-10-01" @default.
- W4280499295 title "Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy" @default.
- W4280499295 cites W1749022239 @default.
- W4280499295 cites W1757407923 @default.
- W4280499295 cites W1963469729 @default.
- W4280499295 cites W1966900875 @default.
- W4280499295 cites W1972739162 @default.
- W4280499295 cites W1972885091 @default.
- W4280499295 cites W1979242769 @default.
- W4280499295 cites W2015028559 @default.
- W4280499295 cites W2019930901 @default.
- W4280499295 cites W2026084555 @default.
- W4280499295 cites W2055443961 @default.
- W4280499295 cites W2056013092 @default.
- W4280499295 cites W2087720231 @default.
- W4280499295 cites W2089385034 @default.
- W4280499295 cites W2091618582 @default.
- W4280499295 cites W2096183233 @default.
- W4280499295 cites W2097968064 @default.
- W4280499295 cites W2101460388 @default.
- W4280499295 cites W2102005754 @default.
- W4280499295 cites W2108215699 @default.
- W4280499295 cites W2113935263 @default.
- W4280499295 cites W2114503630 @default.
- W4280499295 cites W2125447919 @default.
- W4280499295 cites W2132067697 @default.
- W4280499295 cites W2135172310 @default.
- W4280499295 cites W2135638162 @default.
- W4280499295 cites W2136574772 @default.
- W4280499295 cites W2138787512 @default.
- W4280499295 cites W2145092426 @default.
- W4280499295 cites W2145835533 @default.
- W4280499295 cites W2156143871 @default.
- W4280499295 cites W2156324629 @default.
- W4280499295 cites W2162674813 @default.
- W4280499295 cites W2166156136 @default.
- W4280499295 cites W2166573361 @default.
- W4280499295 cites W2217276639 @default.
- W4280499295 cites W2276228008 @default.
- W4280499295 cites W2283064216 @default.
- W4280499295 cites W2319962899 @default.
- W4280499295 cites W2331300362 @default.
- W4280499295 cites W2337742766 @default.
- W4280499295 cites W2486397717 @default.
- W4280499295 cites W2516068649 @default.
- W4280499295 cites W2519598925 @default.
- W4280499295 cites W2560322684 @default.
- W4280499295 cites W2567125506 @default.
- W4280499295 cites W2590536177 @default.
- W4280499295 cites W2597795073 @default.
- W4280499295 cites W2616485707 @default.
- W4280499295 cites W2757756125 @default.
- W4280499295 cites W2757903295 @default.
- W4280499295 cites W2765108097 @default.
- W4280499295 cites W2775047381 @default.
- W4280499295 cites W2781725933 @default.
- W4280499295 cites W2786753426 @default.
- W4280499295 cites W2794293465 @default.
- W4280499295 cites W2802168390 @default.
- W4280499295 cites W2805157192 @default.
- W4280499295 cites W2806333996 @default.
- W4280499295 cites W2883906054 @default.
- W4280499295 cites W2884468211 @default.
- W4280499295 cites W2884539427 @default.
- W4280499295 cites W2887104019 @default.
- W4280499295 cites W2895913650 @default.
- W4280499295 cites W2903033182 @default.
- W4280499295 cites W2913020475 @default.
- W4280499295 cites W2913928546 @default.
- W4280499295 cites W2942043208 @default.
- W4280499295 cites W2945927256 @default.
- W4280499295 cites W2965435066 @default.
- W4280499295 cites W2971087512 @default.
- W4280499295 cites W2982051641 @default.
- W4280499295 cites W2987921837 @default.
- W4280499295 cites W2991596607 @default.
- W4280499295 cites W3014494596 @default.
- W4280499295 cites W3022456551 @default.
- W4280499295 cites W3036123102 @default.
- W4280499295 cites W3211488171 @default.
- W4280499295 cites W4361866993 @default.
- W4280499295 cites W59174886 @default.
- W4280499295 cites W994786805 @default.
- W4280499295 doi "https://doi.org/10.1080/07853890.2022.2071977" @default.